2seventy bio, Inc. (NASDAQ:TSVT) Q1 2024 Earnings Call Transcript

Chip Baird: Yeah. John, thanks for the question and comments from the FDA. We’re certainly excited, as you said, with the team’s performance there. It’s any time you solve a bottleneck that a new one is created in a supply chain as complex as CAR-T therapy. And so I think with the approval of suspension vector, with the amount of capacity that we’ve been able to establish consistently on the drug product side, you start to think about other bottlenecks, and that could be the number of beds in the clinic. That could be apheresis capacity. These are all things that collectively as an industry we’re thinking about. And to the extent that we can influence, we are, those are ultimately decisions that are made by the academic centers and hospitals, et cetera.

But it’s all part of the broader ecosystem. We’ve been playing a leading role there for some time and we’re going to continue to work to make access and availability for as many patients who can benefit here as we can. And we think that’s a big number and we’re going to be at it for quite some time. Anna, I don’t know if you have any additional thoughts on that one.

Anna Truppel-Hartmann: Thank you, Chip. I think you answered that very well. Thank you.

Operator: Thank you. And I’m currently showing no further questions at this time. I’d like to hand the call back over to Chip Baird for closing remarks.

Chip Baird: Thank you all for calling in today. If you have questions, we’re happy to follow up further and look forward to continuing to get after the return to growth for Abecma here throughout the balance of the year. Thanks, everyone. Have a great day.

Operator: This concludes today’s conference call. Thank you for your participation. You may now disconnect.